GUANGZHOU BURNING ROCK DX CO.,LTD

Burning Rock Dx (NASDAQ: BNR) is a global precision oncology leader specializing in NGS-based diagnostics for both tissue and liquid biopsy. With internationally accredited labs (CLIA, CAP, ISO15189, ISO13485) and deep NGS expertise, the company offers a broad portfolio of in-house assays and integrated solutions across the oncology development cycle. Burning Rock supports pharmaceutical development and decentralized clinical implementation, partnering with biopharma and clinical labs to advance trials, biomarker research, and real-world diagnostics. Key milestones include approvals for multiple IVD kits across NMPA, CE, and MHLW and Breakthrough Device Designations from both the FDA and NMPA for its multi-cancer early detection test. Burning Rock is committed to transforming cancer care through innovative, science-driven solutions.